389 related articles for article (PubMed ID: 15000529)
21. Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome.
Motomura M; Lang B; Johnston I; Palace J; Vincent A; Newsom-Davis J
J Neurol Sci; 1997 Mar; 147(1):35-42. PubMed ID: 9094058
[TBL] [Abstract][Full Text] [Related]
22. Antibodies to recombinant synaptotagmin and calcium channel subtypes in Lambert-Eaton myasthenic syndrome.
Takamori M; Takahashi M; Yasukawa Y; Iwasa K; Nemoto Y; Suenaga A; Nagataki S; Nakamura T
J Neurol Sci; 1995 Nov; 133(1-2):95-101. PubMed ID: 8583238
[TBL] [Abstract][Full Text] [Related]
23. Lambert-Eaton myasthenic syndrome.
Newsom-Davis J
Rev Neurol (Paris); 2004 Feb; 160(2):177-80. PubMed ID: 15034474
[TBL] [Abstract][Full Text] [Related]
24. Antibodies against the calcium channel beta-subunit in Lambert-Eaton myasthenic syndrome.
Verschuuren JJ; Dalmau J; Tunkel R; Lang B; Graus F; Schramm L; Posner JB; Newsom-Davis J; Rosenfeld MR
Neurology; 1998 Feb; 50(2):475-9. PubMed ID: 9484375
[TBL] [Abstract][Full Text] [Related]
25. Lambert-Eaton myasthenic syndrome as an autoimmune calcium channelopathy.
Takamori M
Biochem Biophys Res Commun; 2004 Oct; 322(4):1347-51. PubMed ID: 15336982
[TBL] [Abstract][Full Text] [Related]
26. An autoimmune channelopathy associated with cancer: Lambert-Eaton myasthenic syndrome.
Takamori M
Intern Med; 1999 Feb; 38(2):86-96. PubMed ID: 10225662
[TBL] [Abstract][Full Text] [Related]
27. Cross-linking of presynaptic calcium channels: a mechanism of action for Lambert-Eaton myasthenic syndrome antibodies at the mouse neuromuscular junction.
Peers C; Johnston I; Lang B; Wray D
Neurosci Lett; 1993 Apr; 153(1):45-8. PubMed ID: 8390031
[TBL] [Abstract][Full Text] [Related]
28. Lambert-Eaton myasthenic syndrome: clinical diagnosis, immune-mediated mechanisms, and update on therapies.
Sanders DB
Ann Neurol; 1995 May; 37 Suppl 1():S63-73. PubMed ID: 8968218
[TBL] [Abstract][Full Text] [Related]
29. Lambert-eaton myasthenic syndrome differential reactivity of tumor versus non-tumor patients to subunits of the voltage-gated calcium channel.
Pellkofer HL; Armbruster L; Krumbholz M; Titulaer MJ; Verschuuren JJ; Schumm F; Voltz R
J Neuroimmunol; 2008 Nov; 204(1-2):136-9. PubMed ID: 18809213
[TBL] [Abstract][Full Text] [Related]
30. Autoimmune disorders of neuromuscular transmission.
Mahadeva B; Phillips LH; Juel VC
Semin Neurol; 2008 Apr; 28(2):212-27. PubMed ID: 18351523
[TBL] [Abstract][Full Text] [Related]
31. Human autoantibodies specific for the alpha1A calcium channel subunit reduce both P-type and Q-type calcium currents in cerebellar neurons.
Pinto A; Gillard S; Moss F; Whyte K; Brust P; Williams M; Stauderman K; Harpold M; Lang B; Newsom-Davis J; Bleakman D; Lodge D; Boot J
Proc Natl Acad Sci U S A; 1998 Jul; 95(14):8328-33. PubMed ID: 9653186
[TBL] [Abstract][Full Text] [Related]
32. Serum and plasma from patients with Lambert-Eaton Myasthenic Syndrome reduce depolarization-dependent uptake of 45Ca2+ into rat cortical synaptosomes.
Hewett SJ; Atchison WD
Brain Res; 1991 Dec; 566(1-2):320-4. PubMed ID: 1814548
[TBL] [Abstract][Full Text] [Related]
33. Calcium channel subtypes contributing to acetylcholine release from normal, 4-aminopyridine-treated and myasthenic syndrome auto-antibodies-affected neuromuscular junctions.
Giovannini F; Sher E; Webster R; Boot J; Lang B
Br J Pharmacol; 2002 Aug; 136(8):1135-45. PubMed ID: 12163346
[TBL] [Abstract][Full Text] [Related]
34. [Editorial introduction: from the structure and functions of the neuromuscular junction to the diseases].
Takamori M
Brain Nerve; 2011 Jul; 63(7):635-40. PubMed ID: 21747132
[TBL] [Abstract][Full Text] [Related]
35. Disruption of synaptosomal calcium channel function by Lambert-Eaton myasthenic immunoglobulin is serum-dependent.
Hewett SJ; Atchison WD
Brain Res; 1992 Dec; 599(2):317-23. PubMed ID: 1363288
[TBL] [Abstract][Full Text] [Related]
36. Lambert-Eaton antibodies inhibit Ca2+ currents but paradoxically increase exocytosis during stimulus trains in bovine adrenal chromaffin cells.
Engisch KL; Rich MM; Cook N; Nowycky MC
J Neurosci; 1999 May; 19(9):3384-95. PubMed ID: 10212298
[TBL] [Abstract][Full Text] [Related]
37. Lambert-Eaton myasthenic syndrome.
Newsom-Davis J
Springer Semin Immunopathol; 1985; 8(1-2):129-40. PubMed ID: 2988146
[TBL] [Abstract][Full Text] [Related]
38. Lambert-Eaton myasthenic syndrome.
Mareska M; Gutmann L
Semin Neurol; 2004 Jun; 24(2):149-53. PubMed ID: 15257511
[TBL] [Abstract][Full Text] [Related]
39. 3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome.
Wirtz PW; Titulaer MJ; Gerven JM; Verschuuren JJ
Expert Rev Clin Immunol; 2010 Nov; 6(6):867-74. PubMed ID: 20979551
[TBL] [Abstract][Full Text] [Related]
40. The synaptic vesicle protein synaptotagmin associates with calcium channels and is a putative Lambert-Eaton myasthenic syndrome antigen.
Leveque C; Hoshino T; David P; Shoji-Kasai Y; Leys K; Omori A; Lang B; el Far O; Sato K; Martin-Moutot N
Proc Natl Acad Sci U S A; 1992 Apr; 89(8):3625-9. PubMed ID: 1314395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
